Background: The presence of jaundice or an abdominal lump in gall bladder cancer (GBC) is often translated to advanced and unresectable disease. We examined whether this was true. Methods: We retrospectively analysed 120 GBC patients, who had been operated on, for presenting symptoms, staging and resectability. The outcomes in patients with jaundice and/or an abdominal lump were compared with those who did not have these features. Early disease was represented by stages I and II, while stages III and IV represented advanced disease. Results: Sixty-eight patients (57%) presented with an abdominal lump and 62 (52%) had jaundice. An abdominal lump, jaundice or both were present in 89 patients (74%), of whom 78 (88%) had advanced disease, while 22 of the 31 patients (71%) with neither jaundice nor an abdominal lump had advanced disease. Forty-four patients (50%) with either or both of these features had R0 resections, while 20 patients (64%) with neither jaundice nor an abdominal lump had R0 resections. The presence of jaundice or an abdominal lump was significantly associated with advanced disease (p = 0.025), but not with unresectability (p = 1). Conclusions: Jaundice or an abdominal lump was present in 74% of the patients with GBC. While this represented advanced-stage cancer, it did not preclude resectability.

1.
Fong Y, Hefferman N, Blumgart LH: Gall bladder carcinoma discovered during laparoscopic cholecystectomy: aggressive resection is beneficial. Cancer 1998;83:423–427.
2.
Shirai Y, Yoshida K, Tsukada K, Muto T, Watanabe H: Radical surgery for gallbladder carcinoma: long-term results. Ann Surg 1992;216:565–568.
3.
Bartlett DL, Fong Y, Fortner JG, Brennan MF, Blumgart LH: Long-term results after resection for gall bladder carcinoma: implications for staging and management. Ann Surg 1996;224:639–646.
4.
Misra NC, Misra S, Chaturvedi A: Carcinoma of the gallbladder; in Johnson CD, Taylor I (eds): Recent Advances in Surgery. London, Churchill Levingston, 1997, vol 20, pp 69–87.
5.
National Cancer Registry Programme: Biennial report 1988–89. New Delhi, Indian Council of Medical Research, 1992, pp 14–15.
6.
Sikora SS, Kapoor R, Pradeep R, Kapoor VK, Saxena R, Kaushik SP: Palliative surgical treatment of malignant obstructive jaundice. Eur Surg Oncol 1994;20:580–584.
7.
Peihler JM, Crichlow RW: Primary carcinoma of the gallbladder. Surg Gynecol Obstet 1978;147:929–942.
8.
Beltz WR, Condon RE: Primary carcinoma of the gallbladder. Ann Surg 1974;180:180–184.
9.
Miyazaki M, Itoh H, Ambiru S, Shimizu H, Togawa A, Gohchi E, Nakajima N, Suwa T: Radical surgery for advanced gallbladder carcinoma. Br J Surg 1996;83:478–481.
10.
Nakamura S, Sakaguchi S, Suzuki S, Muro H: Aggressive surgery for carcinoma of the gall bladder. Surgery 1989;106:467–473.
11.
Gall FP, Köcherling F, Scheele J, Schneider C, Hohenberger W: Radical operations for carcinoma of the gallbladder: present status in Germany. World J Surg 1991;15:328–336.
12.
Onoyama H, Yamamoto M, Tseng A, Ajiki T, Saitoh Y: Extended cholecystectomy for carcinoma of the gallbladder. World J Surg 1995;19:758–763.
13.
Behari A, Sikora SS, Wagholikar GD, Kumar A, Kapoor VK: Longterm survival after extended resection in patients with gallbladder cancer. J Am Coll Surg 2003;196:82–88.
14.
Todoroki T, Kawamoto T, Takahashi H, Takada Y, Koike N, Otsuda M, Fukao K: Treatment of gallbladder cancer by radical resection. Br J Surg 1999;89:622–627.
15.
Grobmyer SR, Lieberman MD, Daly JM: Gallbladder cancer in the twentieth century: single institution’s experience. World J Surg 2004;28:47–49.
16.
Blumgart LH, Fong Y: Surgical management of colorectal metastases to the liver. Curr Prob Surg 1995;5:333–428.
17.
Chijiiwa K, Noshiro H, Nakano K, Okido M, Sugitani A, Yamaguchi K, Tanaka M: Role of surgery for gallbladder carcinoma with special reference to lymph node metastasis and stage using Western and Japanese classification systems. World J Surg 2000;24:1271–1277.
18.
Hawkins WG, DeMatteo RP, Jarnargin WR, Ben-Porat L, Blumgart LH, Fong Y: Jaundice predicts advanced disease and early mortality in patients with gall bladder cancer. Ann Surg Oncol 2004;11:310–315.
19.
Dixon E, Vollmer CM, Sahajpal A, Cattral M, Grant D, Doig C, Hemming A, Taylor B, Langer B, Greig P, Gallinger S: An aggressive surgical approach leads to improved survival in patients with gallbladder cancer: a 12-year study at a North American center. Ann Surg 2005;241:385–394.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.